What are your top takeaways in GU Cancers from ASCO 2023?

1. THOR study. Improved overall survival (HR 0.64 p=0.005) and PFS (HR 0.58 p=0.0002) of the oral FGFR tyrosine kinase inhibitor erdafitinib in FGFR altered metastatic urothelial carcinoma over chemotherapy. Establishes a new standard of care in the second/third/fourth line setting after failure of ch...

ASCO 2023: KEY BLADDER CANCER/UROTHELIAL CARCINOMA (UC) PRESENTATIONS

1. THOR Phase III trial (Abstract: LBA 4619): Erdafitinib (pan-FGFR oral TKI) extended overall survival (OS) v taxane or vinflunine chemotherapy (median 12.1 v 7.8 mo, HR 0.64, p=0.005) in advanced UC (n=266) with FGFR3/2 activating...

1. TALAPRO-2 - Further validation of the use of a PARP inhibitor + and AR pathway inhibitor in men with CRPC and an HRR mutation (esp BRCA 1 and 2).
2. CONTACT-03 - No benefit to adding Atezolizumab to Cabozantinib in second line after immunotherapy in patients with metastatic ccRCC.
3. Development and vali...

1. THOR phase 3 trial (Loriot et al.)
2. VESPER phase 3 trial (Pfister et al.)
3. SWOG 1011 phase 3 trial (Lerner et al.)